Truist on Praxis Precision Medicines Inc. (PRAX): 'We see Significant Upside Potential To Our Base Case'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $500.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
